系统性红斑狼疮相关巨噬细胞活化综合征患者的广泛血清生物标志物分析。
Extensive serum biomarker analysis in patients with macrophage activation syndrome associated with systemic lupus erythematosus.
机构信息
Department of Pediatrics, School of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.
Department of Pediatrics, School of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.
出版信息
Clin Immunol. 2019 Nov;208:108255. doi: 10.1016/j.clim.2019.108255. Epub 2019 Aug 30.
The present study employed an antibody array that simultaneously detects 174 cytokines to identify cytokines involved in the development of macrophage activation syndrome (MAS) associated with systemic lupus erythematosus (SLE) with a view to elucidating potential predictive markers. Eight SLE patients, including four with MAS, were analyzed. Levels of 31 cytokines were significantly elevated in the MAS phase compared with those in the active phase of SLE. Among these cytokines, the MAS/active phase ratios of CXCL9 and soluble tumor necrosis factor receptor II (sTNFR-II) were highest. Elevated serum CXCL9 and sTNFR-II levels during the MAS phase were confirmed by ELISA and were strongly correlated with other inflammatory markers, reflecting the disease activity of MAS associated with SLE. These results highlight the clinical significance of serum CXCL-9 and sTNFR-II levels, and indicate they may be useful biomarkers for the diagnosis of MAS associated with SLE.
本研究采用抗体芯片同时检测 174 种细胞因子，以鉴定与系统性红斑狼疮（SLE）相关的巨噬细胞活化综合征（MAS）发展相关的细胞因子，以期阐明潜在的预测标志物。分析了 8 名 SLE 患者，其中包括 4 名 MAS 患者。与 SLE 的活动期相比，MAS 期的 31 种细胞因子水平显著升高。在这些细胞因子中，CXCL9 和可溶性肿瘤坏死因子受体 II（sTNFR-II）的 MAS/活动期比值最高。通过 ELISA 确认了 MAS 期血清 CXCL9 和 sTNFR-II 水平升高，并且与其他炎症标志物强烈相关，反映了与 SLE 相关的 MAS 的疾病活动。这些结果突出了血清 CXCL-9 和 sTNFR-II 水平的临床意义，并表明它们可能是用于诊断与 SLE 相关的 MAS 的有用生物标志物。
Zotero 插件